sympathetic nervous system; defense response; acute stress; endocannabinoids; rat THE MIDBRAIN PERIAQUEDUCTAL gray (PAG) is a key site of integration of the autonomic, behavioral and antinociceptive components of defensive behavior, associated with responses to acute stress (18) . Neuronal activation by microinjection of excitatory amino acid agonists at dorsal periaqueductal gray (dPAG) sites can produce the full pattern of defensive behavior (1, 16) , including sympathoexcitation and increased blood pressure. Evidence demonstrates a tonic inhibitory influence by GABA (10) , suggesting that a balance between glutamatergic and GABAergic neurotransmission in the defense pathway in the dPAG could set an ongoing level of activation of the alerting system. Dorsal PAG administration of GABA receptor antagonists has been shown to enhance, while GABA agonists suppressed, defense-related behavior (27) . Cardiovascular components are similarly affected, with dPAG microinjection of the GABA receptor antagonist bicuculline evoking increases in heart rate and blood pressure (22) . Recent data demonstrate that blockade of cannabinoid 1 (CB1) receptors in the dPAG attenuates the sympathoexcitatory and pressor components evoked by stimulation of the hypothalamus, suggesting that a similar mechanism may work in models of acute stress (8) .
Although these data suggest that endocannabinoids can modulate sympathetic and pressor responses at the level of the dPAG, the mechanism of action is not known.
Evidence from brain slices indicates that endocannabinoids can act to modulate presynaptic GABA release, leading to disinhibition of postsynaptic neurons and/or depolarizationinduced suppression of inhibition (7, 12, 32, 33) . Recent studies implicate this mechanism in modulation of the autonomic and cardiovascular systems (6, 13) . Endocannabinoid modulation of presynaptic GABA release to second-order baroreceptive neurons in the nucleus tractus solitarius (NTS) has been shown to prolong baroreceptor-mediated inhibition of sympathetic nerve activity (5, 6) . In the PAG, endocannabinoid modulation of GABA transmission was found to reverse the electroacupuncture attenuation of blood pressure changes during visceral afferent stimulation (13, 30) .
At the level of the dPAG, endocannabinoids can influence autonomic and cardiovascular components of acute stress (8) , which are also thought to be under tonic GABAergic inhibition. Therefore, it is hypothesized that endocannabinoid inhibition of GABA release at the level of the dPAG could lead to disinhibition of output neurons, resulting in sympathoexcitation and increases in blood pressure. The present study was performed to examine GABA restraint of sympathetic nerve activity in the dPAG and determine whether endocannabinoid modulation of GABA neurotransmission could play a role in the elaboration of sympathetic and pressor components of defensive behavior.
MATERIALS AND METHODS
The protocol for this study was approved by the Animal Care and Use Committees at the Medical College of Wisconsin and at the Zablocki Department of Veterans Affairs Center. The experiments were performed in Sprague-Dawley rats (350 -390 g) anesthetized with pentobarbital sodium (50 mg/kg ip) with a catheter inserted into a femoral vein for supplemental administration of anesthetic with supplemental doses (2 mg/kg iv) administered as necessary to block the toe pinch reflex in unparalyzed animals. Arterial blood pressure was monitored continuously from a cannula inserted into a tail artery, connected via a pressure transducer to a computer-based data acquisition and storage system (Apple Macintosh G4 computer, PowerLab/ 8SP with chart software; AD Instruments, Colorado Springs, CO). The trachea was cannulated through a midline cervical incision for ventilation with room air (Harvard 683 respirator) when paralyzed prior to gabazine microinjection. A heating pad was used to maintain body temperature at 37°C. The head of the animal was fixed in a stereotaxic frame (Kopf, Tujunga, CA), and a renal nerve was exposed retroperitoneally. Renal sympathetic nerve activity was recorded using flexible silver-wire electrodes positioned on a renal nerve. The electrodes were fixed in position with silica gel, which allows adjustment of the body of the animal without disturbing the recording. The electrophysiological signals were directed to high-impedance differential amplifiers (gain ϭ 1,000; 0.1-10-kHz passband), followed by filter/amplifiers (gain up to 400; high-and low-pass filtering 10 Hz-3 kHz). The amplifier output was displayed online and also directed to precision full-wave rectifiers and averaged using Bessel linear averaging filters (averaging interval ϭ 100 mS) to obtain an online moving time average. Arterial blood pressure, renal sympathetic nerve activity, and a moving-time average of renal sympathetic nerve activity were monitored and recorded on the computer-based data acquisition system. Raw signals were also recorded on tape (Vetter PCM recording adaptor model 3000A) for backup and subsequent data analysis.
In all animals, a dorsal craniotomy was performed, and the dura was reflected to allow the insertion of a four-barrelled glass micropipette (20-m total tip diameter), attached to a pressure ejection system to microinject test agents into the brain. The test agents microinjected in these studies were the synaptic excitant DL-homocysteic acid (DLH; 4 mM; Sigma Chemicals, St. Louis, MO); the endocannabinoid and CB1 receptor agonist anandamide diluted in 0.01% Tocrisolve100 (50 M; Tocris Cookson, St. Louis, MO); and the GABAA receptor antagonist gabazine (200 M; Tocris Cookson). At the end of each study, pontamine sky blue dye (1%; 35 nl; VWR International, Radnor, PA) was microinjected to mark the location of the microinjection site. The micropipette was advanced into the midbrain slowly using a microdrive, targeting the dPAG at a site identified functionally, as described below. The initial coordinates (in mm) with respect to bregma, midline, and dorsal surface were Ϫ7.2, 0.5, and 4.0. The volume of injectate was measured by observing the level of the fluid meniscus through a graduated monocular microscope eyepiece (7 nl/div) and ranged from 14 to 50 nl. Vehicle control and reproducibility of response data were published previously (8) .
DLH protocol. The synaptic excitant, DLH (14 nl) was microinjected to identify a site from which the components of defensive behavior could be evoked. With fine adjustment of the micropipette as necessary, a site was located at which a pressor response with an increase greater than 10 mmHg and an accompanying increase in renal sympathetic nerve activity was evoked. The cardiovascular effects were often accompanied by twitching of the whiskers, hyperventilation, and sometimes movement of the tail and limbs. This protocol was used to indicate tip placement in the defense pathway in the dPAG (8) , and the multibarrelled micropipette remained in place for the duration of the study. Following recovery from the DLH protocol, one of two protocols was followed during which the sympathetic nerve and blood pressure responses were recorded.
Gabazine protocol. The GABAA receptor antagonist gabazine (35 nl) was microinjected to determine whether renal sympathetic nerve activity is under tonic GABAergic inhibition in the dPAG. A DLHsensitive site was identified by following the protocol outlined above. After baseline parameters were regained, gabazine was microinjected at the same site, and renal sympathetic nerve activity and blood pressure were monitored until levels returned to baseline. In three of the initial rats in which this protocol was followed, microinjection of gabazine elicited an increase in renal sympathetic nerve activity and blood pressure followed by burst episodes of gross motor movements, which caused movement of the renal nerve electrode and loss of signal. These experiments were terminated and in subsequent experiments, rats were paralyzed and ventilated with room air after the DLH protocol was performed to identify the injection site in the dPAG. Prior to neuromuscular blockade, adequate anesthesia was assessed by absence of a withdrawal response to a noxious toe pinch and stability of baseline sympathetic nerve activity and blood pressure. In the unparalyzed state, supplemental anesthetic was required approximately every 60 min. For paralysis, an initial dose of pancuronium bromide (0.1 mg/kg iv) was given with additional doses (0.05 mg/kg) required in ϳ90-min intervals, In these studies, a supplemental dose of anesthetic was given prior to pancuronium blockade, which maintained stable nerve activity and blood pressure recordings, indicative of adequate anesthesia, for the duration of the gabazine and anandamide protocols (Table 1) . Additional anesthetic was usually necessary in the extended 60-min gabazine recovery period consistent with the supplementary anesthetic time frame determined prior to pancuronium administration. Baseline nerve activity is a reliable indicator of plane of anesthesia, with increases seen as the depth of anesthesia decreases. As seen in Table 1 , baseline sympathetic nerve activity remained stable before and after neuromuscular blockade, confirming adequate and consistent anesthesia for the duration of the study.
Anandamide protocol. In a separate series of experiments, the DLH protocol was followed to target the dPAG, after which the endocannabinoid CB1 receptor agonist anandamide (35 nl) was microinjected to identify sites from which anandamide could also elicit an increase in sympathetic nerve activity and blood pressure (8) . When there was no response to anandamide, the electrode was repositioned and the DLH protocol was repeated, followed by anandamide microinjection to locate a site from which sympathoexcitation and pressor responses were evoked. After recovery of baseline parameters, gabazine was microinjected, and 1 min later, anandamide microinjection was repeated to determine whether loss of GABAA receptors altered endocannabinoid-evoked sympathoexcitation. Subsequent microinjection of DLH was repeated within 2 min to examine responses to direct neuronal activation after GABA receptor blockade. The recovery response to anandamide microinjection was then assessed at 30 -60 min after gabazine.
Histological identification protocol. At the conclusion of all microinjection protocols, pontamine sky blue dye was microinjected, and the brain was immediately removed and frozen. To identify the location of central microinjection sites, sequential 25-m frozen, transverse sections were cut, stained with neutral red, and examined microscopically to visualize sites marked by the dye. Diagrammatic representations of the location of microinjection sites were compiled.
Data analysis. Analysis of taped data was performed by sampling blood pressure and averaged renal sympathetic nerve activity at a rate of 50 Hz using a PC computer built in-house with a 12-bit A/D converter running programs written in HTBasic. Blood pressure and averaged renal sympathetic nerve activity were displayed along with a movable cursor. The cursor was set at the onset of the microinjection and acted as a zero time marker for the analysis. For the microinjection studies, data were collected and averaged in sequential 10-s periods from 40 s prior to microinjection (baseline), to 1 min after baseline levels were regained. To eliminate noise, zero renal sympathetic nerve activity was obtained at the end of the experiment by crushing the nerve proximal to the recording electrodes, averaging the remaining noise level, and subtracting it from the averaged activity. Nerve activity data were subsequently expressed as percentage changes from baseline immediately preceding each microinjection. The percentage changes in renal sympathetic nerve activity and the absolute changes in blood pressure for each 10-s postmicroinjection period were compared using one-way ANOVA for the DLH and for the gabazine protocols. Responses to microinjection of anandamide and DLH were compared before and after microinjection of gabazine and to recovery responses using a two-way ANOVA with repeated measures. All significantly different means were located using the Duncan's post hoc test with significance set at P Ͻ 0.05.
RESULTS
DLH protocol. For all protocols that followed, the excitatory amino acid DLH was microinjected into the dPAG to identify sites from which autonomic and cardiovascular components fundamental to acute stress and typical of a defense response could be evoked. These included an abrupt increase in renal sympathetic nerve activity and an increase in arterial blood pressure (Fig. 1A) . These responses were often accompanied by movement of the vibrissae, hyperventilation, and occasionally movement of the limbs and tail. The onset of the response was immediate and lasted for ϳ1 min, while renal sympathetic nerve activity peaked at 40-50% above baseline at ϳ30 -40 s. Animals were paralyzed and ventilated after electrode placement, preventing further assessment of movement and respiration.
Gabazine protocol. Microinjection of the GABAA receptor antagonist gabazine at DLH-sensitive sites could elicit three patterns of sympathetic and blood pressure response. Two patterns included initial increases in sympathetic nerve activity and blood pressure with the responses lasting ϳ1 min (Fig. 1,  B and C) . At these sites, sympathetic nerve activity peaked at 35.6 Ϯ 10.5% (n ϭ 13) above baseline at 30 s after microinjection, before returning to baseline levels by 60 s. Blood pressure followed a similar pattern, with the peak increase of 10 Ϯ 2 mmHg at 40 s but a slower decline to baseline. At 7/13 of these sites, baseline nerve activity remained stable after the initial excitatory response but at 6/13 sites, sporadic bursting episodes of sympathetic nerve activity and, consequently, blood pressure were evident with an onset 2-3 min after gabazine microinjection (Fig. 1C) . The bursts in nerve activity were of ϳ2-s duration and declined over time, lasting at least 30 min, after which baseline sympathetic nerve activity and blood pressure returned.
Histological examination showed that gabazine microinjection elicited sympathoexcitatory and pressor responses from sites in the dorsomedial and dorsolateral columns of the periaqueductal gray from 5.8 to 7.8 mm caudal to bregma (Fig. 2) . Sites from which the delayed bursting response was evoked appeared to be located at more medial sites than those from which no delayed bursting was evident, although there was a definite overlap in the dorsolateral region. While the bursting sites were located at all rostrocaudal levels, there was a predominant cluster at more rostral sites.
At 10 dPAG sites, from which an increase in response to DLH was elicited, there was no sympathetic or cardiovascular response to microinjection of gabazine. Neither renal sympathetic nerve activity nor blood pressure deviated from baseline levels. A gabazine response could not be predicted on the basis of the response to the DLH protocol, as the magnitudes of the sympathetic and pressor responses to the DLH protocol were not significantly different between sites responding to gabazine and those that did not. The sites from which there was no response to gabazine were also distributed rostrocaudally in the dorsal regions of the PAG and could not be differentiated from those from which a response to gabazine was evident (Fig. 2) .
Anandamide protocol. In another group of animals (n ϭ 13), the DLH protocol elicited sympathetic and cardiovascular responses of the same magnitude and time course as those observed for the gabazine protocol with a peak sympathoexci- (8). The anandamide-evoked sympathoexcitation peaked at 35.5 Ϯ 7.1% above baseline at 30 s following microinjection accompanied by a change in blood pressure of 11 Ϯ 2 mmHg, with the responses declining to baseline levels by 60 -70 s (Fig. 6 ). Subsequent microinjection of gabazine at the same site also elicited an initial increase in renal sympathetic nerve activity and arterial blood pressure. As seen in the gabazine protocol, in some animals (4/13), gabazine had no additional effect (Fig. 3C ), while in others (9/13), gabazine produced a delayed bursting response (Fig. 4C ). The magnitude of the initial responses of renal sympathetic nerve activity and blood pressure were not significantly different to those responding to the gabazine protocol that did not have any microinjection of anandamide, with renal sympathetic nerve activity reaching a peak of 37.4 Ϯ 6.4% above baseline and a pressor response of 7 Ϯ 2 mmHg before declining to baseline levels. However, the sympathetic response to anandamide was attenuated following microinjection of gabazine, regardless of whether subsequent burst episodes in renal sympathetic nerve activity and blood pressure were evident (Figs. 3C and 4C). The peak sympathoexcitation was significantly reduced to 7 Ϯ 3.1% (n ϭ 13) over baseline, and the change in blood pressure significantly reduced to 4 Ϯ 1 mmHg (Fig. 6) . In contrast to the anandamide response, the peak sympathetic response to DLH was significantly increased after gabazine microinjection, reaching values of 68.6 Ϯ 16.5% above baseline, although the pressor response was unchanged (Fig. 5 ). There was little recovery of the response to anandamide at 30 min, and full recovery of the peak anandamide-evoked response on sympathetic nerve activity was evident at 60 min after gabazine microinjection with peak sympathoexcitation at 27.6 Ϯ 5.8% above control (Figs. 3, E and F, 4E, and 6 ). However, compared with the anandamide microinjection prior to gabazine, the onset of the sympathoexcitation was enhanced and the sympathetic nerve activity remained significantly elevated after the peak up to the 90-s time point (Fig. 6) .
The baseline values of renal sympathetic nerve activity prior to each drug microinjection were not significantly different, although there was greater variation prior to DLH microinjection after gabazine and anandamide recovery response, which reached significance for blood pressure (Table 1) .
DISCUSSION
Microinjection of the excitatory amino acid DLH in the dPAG can evoke an increase in sympathetic nerve activity and blood pressure often accompanied by twitching of the whiskers, hyperventilation, and sometimes movement of the limbs. These changes are characteristic of neuronal activation along the defense pathway, which can produce autonomic, cardiovascular, nociceptive, and behavioral elements related to stress, anxiety, panic, and fear (1, 4, 8, 9, 16, 19) . Sympathoexcitation and an increase in arterial blood pressure are key components of acute stress, as exemplified by the defense response and are coordinated in the dorsal PAG (4, 14, 20, 23) . Increases in sympathetic nerve activity and blood pressure mediated by excitatory amino acid transmission in the dPAG are refined by neuromodulators to shape the final output response. The present study demonstrates that blockade of GABAA receptors in the dPAG elicits renal sympathoexcitation, indicating that the sympathetic component is under tonic inhibitory GABAergic control at this level. A recent study showed that endocannabinoid activation of CB1 receptors also plays a role in the modulation or mediation of the sympathetic and cardiovascular components evoked from stimulation of the dPAG (8) . In the present study, GABAA receptor blockade attenuated the cannabinoid-induced sympathoexcitation and pressor response, suggesting an interaction between endocannabinoids and GABA to modulate sympathetic nerve activity and blood pressure. In contrast, the sympathoexcitatory response to DLH Fig. 2 . Diagrammatic transverse sections through the midbrain indicating sites of microinjection of gabazine into the periaqueductal gray (PAG) at 5.8, 6.8, and 7.8 mm caudal to bregma. Black circles denote sites from which gabazine could elicit a sympathoexcitatory and pressor response without additional effect; gray circles denote sites from which gabazine could elicit a sympathoexcitatory and pressor response followed by burst activity; and open circles denote sites from which gabazine elicited no response. DR, dorsal raphe. was enhanced following GABA receptor blockade with gabazine. Taken together, these data suggest that cannabinoids can modulate GABA neurotransmission to disinhibit glutamatergic output neurons and elicit sympathoexcitation associated with a stress response.
Although baselines were regained ϳ1 min after microinjection of gabazine, full recovery of the responses to anandamide took 45-60 min after gabazine microinjection, which indicates that GABAA receptor blockade lasts up to an hour. This longer time frame also correlates to the duration of the delayed burst episodes also evoked by gabazine microinjection, providing further support for prolonged receptor blockade. Therefore, the return of sympathetic activity to baseline after gabazine microinjection is more likely related to the limited spread of injectate rather than a transient recovery from a receptor blockade. In the volume microinjected (35 nl), gabazine would block a fraction of the total population of GABAA receptors influencing dPAG output neurons to the renal sympathetic nerve. The initial sympathoexcitatory and pressor responses would initiate baroreflex compensation, not mediated through the dPAG, self-limiting the duration of the evoked response, allowing sympathetic activity and blood pressure to return to baseline levels, although the population of target receptors in the dPAG remain blocked.
It has long been acknowledged that behavioral (3, 11, 24, 27) , cardiovascular (22) , and respiratory (15) components of the defense response are under tonic GABAergic control in the dPAG. The present data demonstrate that the sympathoexcit- atory component is also subject to GABAergic inhibition. The sources of GABA remain unknown, as do the mechanisms of their recruitment during the central processing of the defense response. However, the present data suggest that cannabinoid modulation of GABAergic neurotransmission plays a role in modulation of sympathetic responses. Endocannabinoids are synthesized in response to depolarization and, through retrograde signaling, can presynaptically inhibit release of neurotransmitters, including GABA, resulting in disinhibition of postsynaptic neurons (7, 12) . The data presented here, along with previously reported data (8) , support a synaptic model of stimulus-related release of endocannabinoids causing presynaptic inhibition of tonic GABA release, leading to disinhibition of sympathoexcitatory postsynaptic neurons and sympathetic activation.
Presynaptic inhibition of GABAergic transmission by endocannabinoids as a synaptic mechanism of neuromodulation has previously been shown in the PAG (32) and other brain regions, including the hippocampus (17) , striatum (28), cerebellum (29) , and rostroventromedial medulla (33) . Few studies have assigned a functional role for this mechanism of modulation of synaptic transmission, but recently, roles in cardiovascular control have been identified. Endocannabinoids microinjected into the NTS prolong renal sympathoinhibition in response to baroreceptor activation (25) and increase the activity of barosensitive NTS neurons (26) . In addition, these studies suggested that a GABAA mechanism was involved, initiating a further study, which demonstrated that direct depolarization of second-order baroreceptive NTS neurons induces endocannabinoid release from the neurons leading to activation of presynaptic CB1 receptors and inhibition of GABA release to enhance baroreflex signaling (6) . There is also evidence to support a role for similar endocannabinoid/ GABA interaction in the processing of cardiovascular information in the PAG. Blockade of CB1 receptors in the ventrolateral PAG reversed the electroacupuncture attenuation of blood pressure changes during visceral afferent stimulation. The effect was reversed by blockade of GABA receptors, indicating endocannabinoid inhibition of GABA release (13) , leading to modulation of arterial blood pressure (30) . The present study also suggests a role for cannabinoid modulation of GABAergic neurotransmission in the expression of autonomic and cardiovascular components of defensive behavior at the level of the PAG.
In this study, the sympathoexcitatory response to the excitatory amino acid agonist DLH was enhanced by GABA receptor blockade following gabazine, a finding that might be expected by reduction of inhibitory GABAergic tone to sympathoexcitatory neurons. The effects of microinjection of gabazine would not be limited to presynaptic mechanisms but would also block inhibitory postsynaptic receptors, leading to neuronal excitation, which could also contribute to the augmented response to DLH.
Correlation of the histological and electrophysiological data suggests that the presence or absence of bursting episodes evoked by GABA receptor blockade may correlate to the locations from which threat and flight behavior, respectively, were evoked (18) by excitatory amino acid agonists. Both are types of defensive behavior, with the former being related to rostral dPAG stimulation sites and the latter to caudal sites. Both are associated with hypertension and renal vasoconstriction, suggesting increases in sympathetic tone. The present data could also correlate to the findings of studies describing two types of behavioral activation following microinjection a GABAA receptor antagonist into the PAG of the rat (11, 24) . One was the presence of jumps after initial motor movements, and the other was the absence of jumps but with a low rate of locomotor activity. When evident, the jumps started to occur 1-2 min after microinjection, were explosive, decayed over time, and persisted for up to 30 min following injection, showing a similar time course to the bursting of sympathetic nerve activity in the present study.
The presence of burst sympathetic activity is unlikely to be dependent on either drug dose because the same dose of gabazine had different effects, or spread of drug to adjacent neurons because minimal volumes of injectate were used. The magnitude of the initial response to gabazine was similar to that following anandamide, which would be expected, as anandamide is shown to modulate GABAergic inhibition. However, the bursting response is not evident following anandamide, which suggests an additional GABA mechanism involved in the generation of the bursting response. The GABA network in the dPAG is complex and considered to be integral to intrinsic neuronal circuits and inhibitory to projecting neurons (2, 21, 31) . In this study, disinhibition of local interneurons or ascending/descending projections, which may influence dPAG output neurons or sympathoexcitatory neurons at other central sites, such as the rostroventrolateral medulla, could lead to the elaboration of the burst sympathetic responses seen.
Perspectives and Significance
The data presented here fit a model for release of endocannabinoids leading to presynaptic inhibition of GABA release and loss of restraint on output dPAG neurons (32) and sympathetic pathways (6) . Endocannabinoid modulation of GABAergic inhibition provides a mechanism to increase sympathetic nerve activity and blood pressure via the defense pathway in the dPAG. Its relevance at this level of the neuroaxis may not be limited to a role in enhancing defense responses but may also be involved in the integration of diverse behavioral processes, whose physiological components are established in the same neural networks, including acute stress, anxiety, and fear. In the dPAG, cannabinoid modulation of GABAergic inhibition elicits sympathoexcitation, while in the NTS, similar signaling leads to sympathoinhibition (25) , highlighting a synaptic mechanism that allows for fine tuning of sympathetic nerve responses appropriate to the reflex.
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The author acknowledges the excellent technical assistance of Claudia Hermes and Victoria Woyach. Fig. 5 . Change in RSNA and BP in response to DLH microinjected into the dPAG prior to (black circles) and 3 min after (gray circles) microinjection of gabazine at the same site (n ϭ 13). *Significant difference from pregabazine and baseline, †Significant difference from baseline. Fig. 6 . Change in RSNA and BP in response to AEA microinjected into the dPAG (black circles), AEA following microinjection of gabazine (gray circles), and AEA recovery response at 60 min after GZ (open circles); n ϭ 13. *Significant difference from post gabazine and baseline. †Significant difference from baseline. §Significant difference from pregabazine, AEA recovery, and baseline. a Significant difference from postgabazine, AEA recovery, and baseline (P Ͻ 0.05).
